Global Hospital Acquired Infection Treatment Market Size, Share, Forecast Report, 2020-2027

The global Hospital Acquired Infection Treatment market garnered revenue around USD 31.2 Billion in 2019 and projected to reach USD 38.7 Billion in 2027, with at a compound annual growth rate (CAGR) 2.4% throughout the estimate period from 2020 to 2027.

Hospital acquired infections (HAIs), also known as nosocomial infections, are developed among patients during the course of treatment received in healthcare settings such as hospitals, outpatient surgery centers, dialysis centers, nursing homes and rehabilitation centers. Hospital infections are those infections that occur within 48 hours of hospitalization or after 72 hours of discharge from hospitals or within 30 days after treatment. Currently, major types of hospital infections prevalent worldwide are hospital acquired pneumonia, urinary tract infections, bloodstream infections and surgical site infections.

North America is most attractive region for hospital acquired infection treatment market. High cost associated with bloodstream infection treatment and increasing number of surgical procedures are some of the factors boosting the growth of hospital acquired infection treatment market. Asia-Pacific being the most populated region with high prevalence rate of infections is a potential market for hospital acquired infection treatment.

This research report encompasses precise assessment of the market with the help of comprehensive qualitative insights and supportable prognoses regarding market size, consumption and production. The projections presented in the report have been derived using proven research methodologies and assumptions. It does so by means of comprehensive qualitative insights, historical statistics, and verifiable predictions about market revenue and sales.

The rapidly budding threat owed to the eruption of COVID-19 is impacting lives, communities, businesses, and industries across the globe. With businesses shuttered, flights grounded, COVID-19 is about to affect the global economy in different ways such as by directly upsetting production and demand, by generating supply chain disruption, and by its financial impact on firms and financial markets. Therefore, this report covers COVID-19 outbreak impact analysis on the Hospital Acquired Infection Treatment market under the research study. The market estimates offered in the report are the outcome of in-depth extensive secondary research, primary interviews and in-house professional assessments. These market evaluations have been measured by reviewing the impact of numerous social, political and economic factors coupled with recent market dynamics affecting the Hospital Acquired Infection Treatment market growth.

The global Hospital Acquired Infection Treatment market is characterized by the presence of numerous small as well as medium scale companies. These players are largely focused towards forward integration via raw material production, product manufacturing, and distribution across various industry verticals. The report recognizes numerous crucial manufacturers of the market. This research study aids to comprehend the strategies and associations that companies are converging to survive in this competitive marketplace. This report assists in understanding footprints of the manufacturers with the help of their global revenue, production, capacity and average selling price analysis for period 2016-2027.

Major manufacturers analysed under this study comprises:

the global market include Abbott Laboratories, Pfizer, Inc., Bayer AG, AstraZeneca, F. Hoffmann-La Roche Ltd., Johnson & Johnson Services, Inc., Merck & Co., Inc., Cipla Inc., GlaxoSmithKline plc. Aridis Pharmaceuticals, Inc., Astellas Pharma Inc., Daiichi Sankyo, Inc., Bristol-Myers Squibb Company, and Eli Lilly and Company, among others.

This report delivers market breakdown and its revenue, consumption, production analysis and projections by categorizing it depending on parameters such as type, application/end-user, and region. This research report delivers the analysis and prognosis of revenue, production, price, market share and growth trend for different products such as:

Global Hospital acquired infection treatment (HAI) Market, by Infection Type

Urinary Tract Infection

Ventilator-Associated Pneumonia

Bloodstream Infection

Surgical Site Infection

Others (Gastrointestinal Infection, ENT Infections, Skin Infection and Bone Infection)

Global Hospital acquired infection treatment (HAI) Market, by Treatment

Antibacterial Treatment

Beta-Lactams

Quinolones

Vancomycin

Other

Antiviral Treatment

Acyclovir

Foscarnet

Antifungal Treatment

Amphotericin B

Triazoles

Other (Antiparasitic, Antiprotozoal and Anti TB Treatment)

Regional Analysis and Forecast

Further, this research study analyses market size, production, consumption and its advancement trends at global, regional, and country level for period 2016 to 2027 and covers following region in its scope:

• North America
  • United States
  • Canada
• Europe
  • Germany
  • United Kingdom
  • Italy
  • France
  • Rest of EU
• Asia Pacific
  • China
  • India
  • Japan
  • Southeast Asia
  • Rest of APAC
• Central & South America
  • Brazil
  • Argentina
  • Rest of Central & South America
• Middle East and Africa
  • UAE
  • Saudi Arabia
  • Rest of MEA